ClinicalTrials.Veeva

Menu

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery (PREPACOL2)

A

Assistance Publique - Hôpitaux de Paris

Status and phase

Completed
Phase 3

Conditions

Rectal Cancer Surgery

Treatments

Drug: Oral Placebo Ornidazole
Drug: Oral Placebo Gentamycin
Drug: Sennosides colonic preparation
Drug: Oral Ornidazole
Drug: Oral Gentamycin

Study type

Interventional

Funder types

Other

Identifiers

NCT03491540
P160938J

Details and patient eligibility

About

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone Our hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone

Full description

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

This study's hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone Preoperative mechanical bowel preparation (MBP) has been proposed in an attempt to reduce the colonic fecal load and to limit the risk of surgical site contamination, thus theoretically limiting the risk of postoperative surgical site infection (SSI). However, the benefit of such MBP before colorectal surgery is related to type of procedure performed. Indeed, several randomized controlled trials (RCT) and meta-analyses have demonstrated the absence of benefit of MBP before colon cancer surgery, whereas a recent RCT suggested that MBP before rectal cancer surgery was associated to a significant reduction of postoperative SSI, as compare to the absence of preoperative MBP.

Recent studies suggested that the adjunction of oral antibiotics during MBP could help efficiently reduce the risk of postoperative SSI. Indeed, a recent meta-analysis of RCT have suggested that patients preoperatively receiving both MBP and oral antibiotics were exposed to a significantly reduced risk of postoperative SSI, as compared to patients receiving only preoperative MBP. This result was confirmed in a recent RCT which compared preoperative MBP and oral antibiotics versus MBP alone in a heterogeneous population of patients who underwent laparoscopic colonic or rectal surgery. However, to date, no RCT compared the outcomes of an MBP with oral antibiotics to MBP without oral antibiotics in a homogeneous cohort of patients undergoing rectal cancer surgery.

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

Enrollment

414 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged 18 or more
  • Scheduled to undergo elective restorative laparoscopic cancer of the rectal (<15 cm from the anal margin) with sphincter preservation
  • With Signed consent
  • And affiliated to the French social security system

Exclusion criteria

  • Emergent surgery
  • Scheduled total colo-proctectomy
  • Scheduled abdominoperineal restion with definitive colostomy
  • Scheduled associated concomitant resection of another organ (liver, etc.)
  • Active bacterial infection at the time of surgery or recent antibiotic therapy (up to 15 days before surgery)
  • Associated inflammatory bowel disease
  • Patients with known colonization with multidrug-resistant enterobacteriacea
  • History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used.
  • Cirrhosis of grade B and C (Child-Pugh classification)
  • Myasthenia
  • Allergy to one of the other treatments administered for the purpose of the trial (including betadine)
  • Patient suffering from severe central neurologic diseases, fixed or progressive.
  • Pregnant patients
  • Refusal to participate or inability to provide informed consent

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

414 participants in 2 patient groups, including a placebo group

1) " MBP and oral antibiotics " group
Experimental group
Description:
Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
Treatment:
Drug: Oral Ornidazole
Drug: Sennosides colonic preparation
Drug: Oral Gentamycin
2) " MBP alone " group
Placebo Comparator group
Description:
Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
Treatment:
Drug: Oral Placebo Gentamycin
Drug: Sennosides colonic preparation
Drug: Oral Placebo Ornidazole

Trial contacts and locations

1

Loading...

Central trial contact

Massimo GIACCA, MD; Yves PANIS, MD, phd

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems